Opinions

Jim Cramer - Mad Money Catalent CTLT-N DON'T BUY Nov 29, 2023

They had a financial problem. Stay away for a while.

Jim Cramer - Mad Money

Unknown

Unlock Rating

$39.770

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

BUY

They make the tools that helped Moderna make the Covid vaccine. Roared during the pandemic, then crashed in 2022, but is soaring now. Rumoured that Danaher could take this over.

DON'T BUY

Danaher (he owns) or Illumina could buy CTLT, at least that's the talk. Until something happens, he won't buy this.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Jim Cramer - Mad Money Catalent CTLT-N DON'T BUY Nov 29, 2023

You might be interested:

Catalent(CTLT-N)

Catalent(CTLT-N)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Brendan Caldwell

The Panic-Proof Portfolio (Stockchase Research)

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase Insights

Jim Cramer - Mad Money